Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Abstract CT120: Phase 1 trial of bortezomib and clofarabine combination in adults with refractory solid tumors

Cancer Res (2024) 84 (7_Supplement): CT120.

https://doi.org/10.1158/1538-7445.AM2024-CT120

Published: 05 April 2024

View articletitled, Abstract CT120: Phase 1 trial of bortezomib and clofarabine combination in adults with refractory solid tumors

Journal Articles

Abstract CT115: Phase I trial of the triplet berzosertib (M6620, VX-970), veliparib and cisplatin (BVP) in patients with advanced solid tumors

Geraldine O'Sullivan Coyne, Khanh T. Do, Shivaani Kummar, Naoko Takebe, Sarina Piha-Paul, Richard Piekarz, Deborah Wilsker, Brandon Miller, Katherine Ferry-Galow, Ralph Parchment, Lamin Juwara DNP, Mary Jane Ong, Arjun Mittra, James H. Doroshow, Alice P. Chen

Cancer Res (2021) 81 (13_Supplement): CT115.

https://doi.org/10.1158/1538-7445.AM2021-CT115

Published: 01 July 2021

View articletitled, Abstract CT115: Phase I trial of the triplet berzosertib (M6620, VX-970), veliparib and cisplatin (BVP) in patients with advanced solid tumors

Journal Articles

Abstract 802: Implementation of optimized research biopsy analyses for clinical pharmacodynamic (PD) studies

Katherine V. Ferry-Galow, Deborah Wilsker, Robert J. Kinders, Hala R. Makhlouf, Angie Dull, Tony Navas, Rachel E. Andrews, Geraldine O'Sullivan Coyne, Alice P. Chen, James H. Doroshow, Ralph E. Parchment

Cancer Res (2020) 80 (16_Supplement): 802.

https://doi.org/10.1158/1538-7445.AM2020-802

Published: 15 August 2020

View articletitled, Abstract 802: Implementation of optimized research biopsy analyses for clinical pharmacodynamic (PD) studies

Journal Articles

Abstract 6495: Development of robust and reproducible controls to support clinical implementation of quantitative immunofluorescence assays for pharmacodynamic biomarkers

Gabriel J. Benton, Katherine V. Ferry-Galow, Victor E. Lonsberry, Manisha Mohandoss, Howard Stotler, Debbie Trail, Kyle Georgius, Melinda Hollingshead, Deborah Wilsker, Robert Kinders, James H. Doroshow, Ralph E. Parchment

Cancer Res (2020) 80 (16_Supplement): 6495.

https://doi.org/10.1158/1538-7445.AM2020-6495

Published: 15 August 2020

View articletitled, Abstract 6495: Development of robust and reproducible controls to support clinical implementation of quantitative immunofluorescence assays for pharmacodynamic biomarkers

Journal Articles

Abstract CT099: DNA damage response and therapeutic activity following once-daily administration of the Wee 1 inhibitor AZD1775 (adavosertib)

Cancer Res (2019) 79 (13_Supplement): CT099.

https://doi.org/10.1158/1538-7445.AM2019-CT099

Published: 01 July 2019

View articletitled, Abstract CT099: DNA damage response and therapeutic activity following once-daily administration of the Wee 1 inhibitor AZD1775 (adavosertib)

Journal Articles

The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity

Susan L. Holbeck, Richard Camalier, James A. Crowell, Jeevan Prasaad Govindharajulu, Melinda Hollingshead, Lawrence W. Anderson, Eric Polley, Larry Rubinstein, Apurva Srivastava, Deborah Wilsker, Jerry M. Collins, James H. Doroshow

Cancer Res (2017) 77 (13): 3564–3576.

https://doi.org/10.1158/0008-5472.CAN-17-0489

Published: 01 July 2017

View articletitled, The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity

Includes: Supplementary data

Journal Articles

Abstract 4678: Pilot trial of talazoparib (BMN 673), an oral PARP inhibitor, in patients with advanced solid tumors carrying deleterious BRCA mutations

Robert S. Meehan, Alice P. Chen, Geraldine O’Sullivan Coyne, Shivaani Kummar, Jiuping Ji, Rasa Vilimas, Lamin Juwara, Robert J. Kinders, Katherine Ferry-Galow, Deborah Wilsker, Yiping Zhang, Angie B. Dull, Tony Navas, Lihua Wang, Ralph E. Parchment, James H. Doroshow

Cancer Res (2017) 77 (13_Supplement): 4678.

https://doi.org/10.1158/1538-7445.AM2017-4678

Published: 01 July 2017

View articletitled, Abstract 4678: Pilot trial of talazoparib (BMN 673), an oral PARP inhibitor, in patients with advanced solid tumors carrying deleterious BRCA mutations

Journal Articles

Abstract 3072: A clinical pharmacodynamic biomarker assay that distinguishes potentially repairable, cytotoxic drug-induced DNA double strand breaks (DSBs) from DSBs associated with apoptotic cell death

Angie B. Dull, Deborah Wilsker, Robert J. Kinders, Ralph E. Parchment, David Evans, Beverly A. Teicher, James H. Doroshow

Cancer Res (2017) 77 (13_Supplement): 3072.

https://doi.org/10.1158/1538-7445.AM2017-3072

Published: 01 July 2017

View articletitled, Abstract 3072: A clinical pharmacodynamic biomarker assay that distinguishes potentially repairable, cytotoxic drug-induced DNA double strand breaks (DSBs) from DSBs associated with apoptotic cell death

Journal Articles

Abstract 3341: Development of a multiplex quantitative immunofluorescence assay to evaluate DNA damage repair deficient models in vitro and in vivo and the response to cytotoxic agents.

Allison M. Marrero, Scott M. Lawrence, Deborah Wilsker, Priya Balasubramanian, Robert J. Kinders, Ralph E. Parchment, Joseph E. Tomaszewski, James H. Doroshow

Cancer Res (2013) 73 (8_Supplement): 3341.

https://doi.org/10.1158/1538-7445.AM2013-3341

Published: 15 April 2013

View articletitled, Abstract 3341: Development of a multiplex quantitative immunofluorescence assay to evaluate DNA damage repair deficient models in vitro and in vivo and the response to cytotoxic agents.

Journal Articles

Abstract 1460: Comparison of radiosensitizing effects of several PARP inhibitors under clinical investigation

Stephen S. Yoo, David Cerna, Deborah Wilsker, Beverly A. Teicher, C. Norman Coleman

Cancer Res (2012) 72 (8_Supplement): 1460.

https://doi.org/10.1158/1538-7445.AM2012-1460

Published: 15 April 2012

View articletitled, Abstract 1460: Comparison of radiosensitizing effects of several PARP inhibitors under clinical investigation

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract CT120: Phase 1 trial of bortezomib and clofarabine combination in adults with refractory solid tumors

Abstract CT115: Phase I trial of the triplet berzosertib (M6620, VX-970), veliparib and cisplatin (BVP) in patients with advanced solid tumors

Abstract 802: Implementation of optimized research biopsy analyses for clinical pharmacodynamic (PD) studies

Abstract 6495: Development of robust and reproducible controls to support clinical implementation of quantitative immunofluorescence assays for pharmacodynamic biomarkers

Abstract CT099: DNA damage response and therapeutic activity following once-daily administration of the Wee 1 inhibitor AZD1775 (adavosertib)

The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity

Abstract 4678: Pilot trial of talazoparib (BMN 673), an oral PARP inhibitor, in patients with advanced solid tumors carrying deleterious BRCA mutations

Abstract 3072: A clinical pharmacodynamic biomarker assay that distinguishes potentially repairable, cytotoxic drug-induced DNA double strand breaks (DSBs) from DSBs associated with apoptotic cell death

Abstract 3341: Development of a multiplex quantitative immunofluorescence assay to evaluate DNA damage repair deficient models in vitro and in vivo and the response to cytotoxic agents.

Abstract 1460: Comparison of radiosensitizing effects of several PARP inhibitors under clinical investigation

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only